177 related articles for article (PubMed ID: 20353301)
21. Mucoid Pseudomonas in cystic fibrosis.
Pritt B; O'Brien L; Winn W
Am J Clin Pathol; 2007 Jul; 128(1):32-4. PubMed ID: 17580270
[TBL] [Abstract][Full Text] [Related]
22. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis.
Chotirmall SH; Smith SG; Gunaratnam C; Cosgrove S; Dimitrov BD; O'Neill SJ; Harvey BJ; Greene CM; McElvaney NG
N Engl J Med; 2012 May; 366(21):1978-86. PubMed ID: 22607135
[TBL] [Abstract][Full Text] [Related]
23. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
Murray TS; Egan M; Kazmierczak BI
Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
[TBL] [Abstract][Full Text] [Related]
24. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.
Ciofu O; Mandsberg LF; Wang H; Høiby N
FEMS Immunol Med Microbiol; 2012 Jul; 65(2):215-25. PubMed ID: 22540844
[TBL] [Abstract][Full Text] [Related]
25. Epidemiological investigation and glycotyping of clinical Pseudomonas aeruginosa isolates from patients with cystic fibrosis by mass spectrometry: association with multiple drug resistance.
Altman E; Wang Z; Aaron SD; Liu X; Vandemheen KL; Ferris W; Giesbrecht T; Li J
J Microbiol Methods; 2009 Feb; 76(2):204-8. PubMed ID: 19000720
[TBL] [Abstract][Full Text] [Related]
26. Serotyping and virulence factors of Pseudomonas aeruginosa clinical isolates.
Hostacká A; Majtán V
Acta Microbiol Immunol Hung; 1997; 44(2):141-6. PubMed ID: 9330662
[TBL] [Abstract][Full Text] [Related]
27. Pseudomonas aeruginosa Aggregate Formation in an Alginate Bead Model System Exhibits
Sønderholm M; Kragh KN; Koren K; Jakobsen TH; Darch SE; Alhede M; Jensen PØ; Whiteley M; Kühl M; Bjarnsholt T
Appl Environ Microbiol; 2017 May; 83(9):. PubMed ID: 28258141
[TBL] [Abstract][Full Text] [Related]
28. Subinhibitory concentrations of antibacterial drugs and Pseudomonas aeruginosa virulence factors.
Trancassini M; Giordano A; Magni A; Cipriani P
New Microbiol; 1993 Jul; 16(3):275-9. PubMed ID: 8366823
[TBL] [Abstract][Full Text] [Related]
29. Pathogenesis and clinical manifestations of chronic colonization by Pseudomonas aeruginosa and its biofilms in the airway tract.
Kobayashi H; Kobayashi O; Kawai S
J Infect Chemother; 2009 Jun; 15(3):125-42. PubMed ID: 19554398
[No Abstract] [Full Text] [Related]
30. Alginate production by Pseudomonas putida creates a hydrated microenvironment and contributes to biofilm architecture and stress tolerance under water-limiting conditions.
Chang WS; van de Mortel M; Nielsen L; Nino de Guzman G; Li X; Halverson LJ
J Bacteriol; 2007 Nov; 189(22):8290-9. PubMed ID: 17601783
[TBL] [Abstract][Full Text] [Related]
31. Interference of Pseudomonas aeruginosa signalling and biofilm formation for infection control.
Bjarnsholt T; Tolker-Nielsen T; Høiby N; Givskov M
Expert Rev Mol Med; 2010 Apr; 12():e11. PubMed ID: 20370936
[TBL] [Abstract][Full Text] [Related]
32. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses.
Gellatly SL; Hancock RE
Pathog Dis; 2013 Apr; 67(3):159-73. PubMed ID: 23620179
[TBL] [Abstract][Full Text] [Related]
33. Nitrosative stress inhibits production of the virulence factor alginate in mucoid Pseudomonas aeruginosa.
Wood SR; Firoved AM; Ornatowski W; Mai T; Deretic V; Timmins GS
Free Radic Res; 2007 Feb; 41(2):208-15. PubMed ID: 17364947
[TBL] [Abstract][Full Text] [Related]
34. [Discrepancy in the disk diffusion susceptibility test of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients after anaerobic preincubation and its potential clinical relevance].
Cafini F; García-Rey C; Bas P; Gómez-Lus ML; Sánchez I; Vázquez S; Prieto J
Rev Esp Quimioter; 2012 Dec; 25(4):269-73. PubMed ID: 23303259
[TBL] [Abstract][Full Text] [Related]
35. Analysis of quorum sensing-dependent virulence factor production and its relationship with antimicrobial susceptibility in Pseudomonas aeruginosa respiratory isolates.
Karatuna O; Yagci A
Clin Microbiol Infect; 2010 Dec; 16(12):1770-5. PubMed ID: 20132256
[TBL] [Abstract][Full Text] [Related]
36. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa.
Gooderham WJ; Hancock RE
FEMS Microbiol Rev; 2009 Mar; 33(2):279-94. PubMed ID: 19243444
[TBL] [Abstract][Full Text] [Related]
37. Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa.
Glonti T; Chanishvili N; Taylor PW
J Appl Microbiol; 2010 Feb; 108(2):695-702. PubMed ID: 19709344
[TBL] [Abstract][Full Text] [Related]
38. Microbe Profile:
Diggle SP; Whiteley M
Microbiology (Reading); 2020 Jan; 166(1):30-33. PubMed ID: 31597590
[No Abstract] [Full Text] [Related]
39. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
40. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies.
Høiby N
J Cyst Fibros; 2002 Dec; 1(4):249-54. PubMed ID: 15463822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
